Effect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic Encephalopathy
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Hepatic encephalopathy is responsible for sleep disturbances and daytime sleepiness. The
purpose of our study is to assess sleep quality, quantity, sleep schemes and physical
activity in patients suffering from HE, before and after a 2 weeks treatment with rifaximine,
which is currently given to lower blood ammoniac levels.